Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Dual Targeting of PI3Kδ and PPARα Enhances Antitumor Activity via FoxO1 Activation in Follicular Lymphoma

ABSTRACT: Follicular lymphoma (FL) frequently exhibits relapse and resistance to targeted therapy, underscoring the need for rational combinations. Here, we demonstrate that the phosphoinositide 3-kinase-δ (PI3Kδ) inhibitor linperlisib combined with the pan-peroxisome proliferator-activated receptor (PPAR) agonist chiglitazar delivers robust antitumor activity across FL models, including cell-derived and patient-derived xenografts, with a favorable tolerability profile. The combined regimen enforces G1/S arrest and apoptosis and exerts complementary metabolic–signaling effects by suppressing glycolysis, activating PPARα-driven programs, and relieving PI3K/AKT-mediated repression of forkhead box protein O1 (FoxO1). Genetic depletion of FoxO1 blunts treatment responses, indicating that FoxO1 activity is a pharmacodynamic biomarker and potential predictor of benefit. Compared with monotherapy, the combination consistently achieves superior tumor control in vivo without overt toxicity, indicating clinical translation potential. Collectively, these data support the clinical evaluation of linperlisib plus chiglitazar in FL, with prospective assessment of FoxO1 activity as a pharmacodynamic biomarker.

ORGANISM(S): Homo sapiens

PROVIDER: GSE311442 | GEO | 2026/04/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

A PI3Kδ-Foxo1-FasL signaling amplification loop rewires CD4 T helper cell signaling and differentiation.

Project description:While inputs regulating CD4+ T helper (Th) cell differentiation are well defined, the integration of downstream signaling with transcriptional and epigenetic programs that define Th lineage identity remains incompletely resolved. PI3K signaling is a critical regulator of T cell function; activating mutations affecting PI3Kδ result in an immunodeficiency with multiple T cell defects. Using mice expressing activated PI3Kδ, we found aberrant expression of proinflammatory Th1 signature genes under Th2-inducing conditions, both in vivo and in vitro. This dysregulation was driven by a PI3Kδ-IL-2-Foxo1 signaling amplification loop, fueling Foxo1 inactivation, loss of Th2 lineage restriction, and extensive epigenetic reprogramming. Surprisingly, ablation of Fasl, a Foxo1-repressed gene, normalized both Th2 differentiation and TCR signaling. BioID and imaging revealed Fas interactions with TCR signaling components, which were supported by Fas-mediated potentiation of TCR signaling that could occur in the absence of FADD. Our results highlight Fas-FasL signaling as a critical intermediate in phenotypes driven by activated PI3Kδ, thereby linking two key pathways of immune dysregulation.

2026-02-17 | GSE278337 | GEO

Dual Targeting of PI3Kδ and PPARα Enhances Antitumor Activity via FoxO1 Activation in Follicular Lymphoma

Project description:Dual Targeting of PI3Kδ and PPARα Enhances Antitumor Activity via FoxO1 Activation in Follicular Lymphoma

| PRJNA1369467 | ENA

The PI3Kδ interactome in naïve and activated mouse CD4+ T cells

Project description:Phosphoinositide 3-kinases (PI3Ks) play a central role in adaptive immunity by transducing signals from the T cell antigen receptor (TCR) via production of PIP3. PI3Kδ is a heterodimer composed of a p110δ catalytic subunit associated with a p85α or p85β regulatory subunit and is preferentially engaged by the TCR upon T cell activation. The molecular mechanisms leading to PI3Kδ recruitment and activation at the TCR signalosome remain unclear. In this study, we have used affinity purification coupled with quantitative mass spectrometry to uncover the p110δ interactome in primary CD4+ T cells. Moreover, we have determined how the PI3Kδ interactome changes upon the differentiation of small naïve T cells into T cell blasts expanded in the presence of IL-2.

2021-03-08 | PXD022607 | Pride

PI3Kδ inhibition potentiates glucocorticoids in B-ALL by decreased receptor phosphorylation and enhanced gene regulation

Project description:Glucocorticoids, including dexamethasone and prednisone, are key components of therapy for B-lymphoblastic leukemia (B-ALL) that work through the glucocorticoid receptor (GR). However, glucocorticoids are not effective for all patients, leading to poor outcomes, and the high doses used in chemotherapy cause many toxicities. We have shown that inhibition of the leukocyte restricted PIK3δ is a promising way to specifically enhance glucocorticoids in B-ALL, with the potential to improve outcomes without increasing toxicities. Here, we show that the PI3Kδ inhibitor idelalisib potentiates both prednisolone and dexamethasone in both B-ALL cell lines and primary patient specimens, particularly at sub-saturating doses. Potentiation is partially explained by a widespread enhancement of glucocorticoid gene regulation, including effector genes that drive B-ALL cell death. Idelalisib causes a reduction in direct phosphorylation of GR at S203 and S226. Ablation of these phospho-acceptor sites enhances glucocorticoid potency. Phosphorylation of S226 inhibits GR DNA binding, indicating that PI3Kδ mediated phosphorylation directly inhibits GR function in part though reduction of DNA binding affinity. Thus, PI3Kδ inhibition improves glucocorticoid efficacy in B-ALL in part by decreasing GR phosphorylation and enhancing DNA binding and downstream gene regulation. Identification of this and other contributing mechanisms will help identify patients who can most benefit clinically from this combination therapy.

2022-10-18 | GSE215385 | GEO

A PI3Kδ-Foxo1-FasL signaling amplification loop rewires CD4 T helper cell signaling and differentiation.

Project description:A PI3Kδ-Foxo1-FasL signaling amplification loop rewires CD4 T helper cell signaling and differentiation.

| PRJNA1166676 | ENA

Immunomodulatory effects of PI3Kδ inhibition in murine and human solid tumors [human]

Project description:Phosphoinositide 3-kinase δ (PI3Kδ) plays key roles in lymphocytes and inhibitors targeting this PI3K have been approved for hematological malignancies. While preclinical data in hematological and solid tumor models have demonstrated that PI3Kδ inhibitors (PI3Kδi) can induce anti-tumor immunity, the impact of PI3Kδi in human solid tumors remains unknown. Here, we assessed the effects of the PI3Kδi AMG319 in patients with early stage head and neck cancer in a neoadjuvant, double-blind and placebo-controlled randomised phase-II trial. We find that PI3Kδ inhibition decreases tumor-infiltrating TREG cells and causes heightened cytotoxic potential of tumor-infiltrating CD8+ and CD4+ T cells. Loss of intratumoral TREG cells and an increase in the frequency of activated TREG cells in the blood post-treatment are indicative of systemic effects on TREG cell tissue retention and maintenance. At the chosen AMG319 dosing, the occurrence of immune-related adverse events caused treatment discontinuation in 43% of drug-treated patients, further suggestive of systemic effects on TREG cells. Consistent with this notion, in a murine syngeneic tumor model, PI3Kδi caused a decrease in TREG cells in both tumor and non-malignant tissues and affected TREG subtype composition, maintenance and functionality.

2022-03-02 | GSE166148 | GEO

Immunomodulatory effects of PI3Kδ inhibition in murine and human solid tumors [mouse]

2022-03-02 | GSE166149 | GEO

Enhancer priming role of FOXO1 sustains pro-survival BCR signaling in lymphoma

Project description:Mantle cell lymphoma (MCL) remains incurable requiring new actionable targets. Forkhead Box O1 (FOXO1) exhibits lineage-specific bivalent function as an oncogenic transcription factor that regulates MCL lineage survival function, contrasting with its tumor-suppressor role in other cancer types. Acute degradation of FOXO1-FKBP12F36V by degrader TAG (dTAG) molecules potently induces MCL cell death. Cell cycle restricted degradation of FOXO1 reveals that its function in G1 phase is critical for MCL cell survival. Mechanistically, FOXO1 rapidly reactivates lineage enhancers in the early G1 phase of the cell cycle following the cell division through collaborating with SWI/SNF chromatin remodelers. This interaction facilitates binding and activation of transcription factor PAX5-driven oncogenic MCL lineage gene regulatory networks. Multiomic analysis of FOXO1-dependent transcriptomic changes shows that BCR signaling pathway depends on functional FOXO1 expression. BTK inhibitor combination accelerates G1-specific degradation of FOXO1-caused MCL cell death. Consistently, combined FOXO1 and BTK inhibitors effectively suppress progression of primary MCL cells and MCL xenografts. Our results uncover the molecular networks through which FOXO1 drives MCL lineage survival that can serve as a rationale for a combinatorial targeting of FOXO1 network components with Bruton’s tyrosine kinase inhibitors and explain the mechanism underlying its lineage-restricted oncogenic bivalent activity.

2025-07-30 | GSE303985 | GEO

Regression of Post-Prandial Cardiac Hypertrophy in Burmese Pythons is Mediated by FoxO1

Project description:As ambush-hunting predators that consume large prey after long intervals of fasting, Burmese pythons evolved with unique adaptations for regulating organ structure and function. Among these is cardiac hypertrophy that develops within three days following a meal (1, 2), which we previously showed was initiated by circulating growth factors (3). Post-prandial cardiac hypertrophy in pythons also rapidly regresses with subsequent fasting (2); however, the molecular mechanisms that regulate the dynamic cardiac remodeling in pythons during digestion are largely unknown. In this study, we employed a multi-omics approach coupled with targeted molecular analyses to examine remodeling of the python ventricular transcriptome and proteome throughout digestion. We found that forkhead box protein O1 (FoxO1) signaling was suppressed prior to hypertrophy development and then activated with regression, which coincided with decreased and then increased expression, respectively, of FoxO1 transcriptional targets involved in protein degradation. To define the molecular mechanistic role of FoxO1 in hypertrophy regression, we used cultured mammalian cardiomyocytes treated with post-fed python plasma. Hypertrophy regression both in pythons and in vitro coincided with activation of FoxO1-dependent autophagy; however, introduction of a FoxO1-specific inhibitor prevented both regression of cell size and autophagy activation. Finally, to determine if FoxO1 activation could induce regression, we generated an adenovirus expressing a constitutively active FoxO1. FoxO1 activation was sufficient to prevent and reverse post-fed plasma-induced hypertrophy, which was partially prevented by autophagy inhibition. Our results indicate that modulation of FoxO1 activity contributes to the dynamic ventricular remodeling in post-prandial Burmese pythons.

2024-09-12 | PXD054079 | Pride

Hepatocyte FoxO1 depletion exacerbates hepatic inflammation in MASH

Project description:The transcription factor Forkhead box protein O1 (FoxO1) is a well-established regulator of glucose and lipid metabolism, yet its role in metabolic dysfunction-associated steatohepatitis (MASH) pathogenesis remains debated. This study investigates hepatocyte-specific FoxO1 mechanisms driving hepatic inflammation in MASH. Using hepatocyte-specific FoxO1-knockout (KO) mice fed a methionine-choline-deficient diet and LPS-treated FoxO1-KO cells, we demonstrate FoxO1 depletion exacerbates hepatic inflammation, ballooning degeneration, and upregulates TNF-alpha, CXCL8, and CXCL2 in vivo and in vitro. Transcriptomics linked FoxO1 deficiency to enriched pro-inflammatory pathways and suppressed cysteine/methionine metabolism.

2025-07-30 | GSE293003 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data